. Author manuscript; available in PMC: 2013 Dec 13.

Published in final edited form as: Am J Perinatol. 2013 Feb 6;30(2):10.1055/s-0033-1334459. doi: 10.1055/s-0033-1334459

Table 3.

Adverse pregnancy outcomes associated with maternal hepatitis C infection following adjustment for demographic factors including tobacco and drug use.

Authors	Source	# HCV ab +	Comparator group	Outcomes
Authors	Source	# HCV ab +	Comparator group	Gestational DM	Pre-maturity	LBW	SGA	Unique Findings
Connell et al.⁴⁶	Florida discharge data 1998–2007	999	1,669,370	NS	OR 1.40 (1.15–1.72)	OR 1.39 (1.11–1.74)	OR 1.19 (0.97–1.46)	Congenital anomalies OR 1.55 (1.14–2.11)
Reddick et al.⁵⁰	NIS 1995–2005 discharge data	555	296,218	OR 1.61 (1–2.59)	OR 1.22 (0.94–1.52)
Pergam et al.⁴⁹	Washington state birth certificate 2003–2005	506	2,024 random selected	If excess wt gain OR 2.51 (1.04–6.03)	OR 1.54 (0.97–2.43)	OR 2.17 (1.24–3.80)	OR 1.46 (1–2.13)	NICU OR 2.91 (1.86–4.55) Neonatal assisted ventilation OR 2.37 (1.46–3.85)
Pergam et al.⁴⁹	Washington state birth certificate 2003–2005	124 drug using	1,439 drug using	QNS	OR 1.03 (0.66–1.61)	OR 1.19 (0.74–1.91)	OR 0.97 (0.57–1.64)	NICU OR 2.80 (1.83–4.29) Neonatal assisted ventilation OR 1.82 (1.03–3.22)
Berkley et al.⁵¹	Univ. New Mexico pregnancy drug treatment program	159 drug using	141 drug using HCV neg.	Not tested	NS	33% vs 17%, adj P = 0.06		Cholestasis of pregnancy (6.3% vs 0%, P = 0.002) Neonatal abstinence syndrome if mother on methadone (88.4% vs 36.4%, P< 0.001)